Statements of Changes in ShareHolders' Equity (Deficit) - USD ($)		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jan. 20, 2021
Beginning balance, shares at Jan. 20, 2021	[1],[2]
Issuance of ordinary shares to Initial Shareholder upon formation			1		1
Issuance of ordinary shares to Initial Shareholder upon formation, shares	[1],[2]	1
Issuance of ordinary shares to Initial Shareholder			37,499		37,499
Issuance of ordinary shares to Initial Shareholder, shares	[1],[2]	2,156,249
Net loss				(8,377)	(8,377)
Ending balance, value at Jul. 31, 2021			37,500	(8,377)	29,123
Ending balance, shares at Jul. 31, 2021	[1],[2]	2,156,250
Net loss				(1,762,838)	(1,762,838)
Sale of 8,625,000 Units through public offering			86,250,000		86,250,000
Sale of 8,625,000 Units through public offering, shares	[1]	8,625,000
Sale of 292,250 Private Units			2,922,500		2,922,500
Sale of 292,250 Private Units, shares	[1]	292,250
Sale of representative’s purchase option			100		100
Underwriters’ commission			(1,725,000)		(1,725,000)
Deferred underwriter commission			(3,018,750)		(3,018,750)
Other offering expenses			(649,588)		(649,588)
Ordinary shares subject to redemption			(71,074,007)		(71,074,007)
Ordinary shares subject to redemption, shares	[1]	(8,625,000)
Subsequent measurement of ordinary shares subject to redemption under ASC 480-10-S99			(12,742,755)	(1,952,335)	(14,695,090)
Ending balance, value at Jul. 31, 2022				$ (3,723,550)	$ (3,723,550)
Ending balance, shares at Jul. 31, 2022	[1]	2,448,500

[1] As of July 31, 2021, this number includes an aggregate of up to 281,250 shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters (see Note 5). As a result of the full exercise of the over-allotment option by the underwriters upon the consummation of the IPO, these shares are no longer subject to forfeiture (see Note 7).

[2] On October 25, 2021, the Company issued additional 718,750 ordinary shares which were purchased by the Sponsor, resulting in an aggregate of 2,156,250 ordinary shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share capitalization (see Note 5).